Salute e Benessere

Scintimun® Commercialization Partnership with Curium Pharma

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine, said, "We are pleased to be bringing Scintimun back to Telix, and see it as a valuable addition to our portfolio. In the near-term, the plan is to increase sales for its current indication by improving product availability, pricing and commercial consistency. There is significant potential to expand clinical utility, including as a "companion imaging" tool for Telix's TLX66 bone marrow conditioning candidate. We…
PR Newswire
13/01/2025

COSRX Launches The Alpha-Arbutin 2 Skin Discoloration Serum

What makesThe Alpha-Arbutin 2 Skin Discoloration Serum exceptional is its powerful blend of five active ingredients, each playing a critical role in targeting skin discoloration to synergistically inhibit melanin production, reduce post-inflammatory hyperpigmentation (PIH), and fade unwanted dark spots. PIH refers to the dark marks left behind after acne or skin irritation, but this serum goes beyond facial concerns, offering a solution for all types of discoloration across the body...
PR Newswire
13/01/2025

Telix to Acquire Next-Generation Therapeutic Assets and Innovative Biologics…

The transaction also includes a state-of-the-art research facility in California, staffed by a talented team of discovery, protein engineering and radiopharmaceutical development experts. Together, these assets will provide Telix with further in-house capabilities in antibody engineering and preclinical development, as well as a novel biologics platform to create the next generation of Telix precision medicine and therapeutic products, beyond the current clinical-stage pipeline. The...
PR Newswire
12/01/2025

BIOVAXYS ANNOUNCES CLOSING OF THIRD TRANCHE OF PRIVATE PLACEMENT

Each Unit consists of one (1) common share in the capital of the Company (each, a "Share") and one (1) whole Share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until January 10, 2027, being the date that is 24 months from the date of issue. Each Unit consists of one (1) common share in the capital of the Company (each, a " Share ") and one (1) whole Share purchase warrant (each, a…
PR Newswire
11/01/2025

Virbac : Declaration of the number of shares and voti

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers)Quotation place: Euronext Paris Compartiment A ISIN code: FR0000031577DateTotal number of shares representing the share capitalTotal number of voting rightsDecember, 31 20248 390 660Gross total of voting...
Nasdaq GlobeNewswire
10/01/2025

Chronic Disease Management: Innovations in Therapeutics, Devices, and Global…

The report on the global market for chronic disease management spotlights trends from 2023, estimates for 2024, and projections through 2029. It evaluates the market potential for various therapeutics and advanced device technologies, covering pharmaceuticals, biologics, traditional and wearable medical devices, and digital therapeutics. The report also examines market drivers, restraints, opportunities, and the competitive landscape. The report on the global market for chronic disease...
PR Newswire
10/01/2025

Sobi's full year 2024 revenue higher than previous estimate

At the publication of the Q3 2024 report on 24 October 2024 Sobi stated the outlook for the full year 2024 to be: Revenue was anticipated to grow by a mid-teens percentage at CER and adjusted EBITA margin was anticipated to be in the mid-30s per cent of revenue. At the publication of the Q3 2024 report on24 October 2024Sobi stated the outlook for the full year 2024 to be: Revenue was anticipated to grow by a mid-teens percentage at CER and adjusted EBITA margin was anticipated to be in the...
PR Newswire
10/01/2025

Ensuring the continuity of IBA's Entrepreneurial Anchoring

Confirmation of the sale of IBA shares to Management AnchorageLouvain-la-Neuve, Belgium, 10 January 2025- IBA (Ion Beam Applications SA), the world leader in particle accelerator technology, confirms that the sale by IBA of up to 633,000 IBA's shares to Management Anchorage, announced in itspress release of 5 December,has been completed on 7 January 2025 at a price of 13.46 euros per share. This sale was carried out by mutual agreement, following the General Meeting of IBA...
Nasdaq GlobeNewswire
10/01/2025

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License…

"We are thrilled to enter our second collaboration with Insilico Medicine, a leader in the field of generative AI, for a highly selective and potentially best-in-class small molecule targeting a broad range of cancers," said Elcin Barker Ergun, CEO of the Menarini Group. "This asset will help us enter into new areas of high unmet need, expanding the tumor areas where we can help cancer patients with ground-breaking therapies." "We are thrilled to enter our second…
PR Newswire
10/01/2025

Refurbished Medical Equipment Market to Hit USD 24.41 Billion by 2029 with 7.6%…

Browse in-depth TOC on "Refurbished Medical Equipment Market"400 - Tables250 - Figures420 - Pages Browse in-depth TOC on "Refurbished Medical Equipment Market" 400 - Tables 250 - Figures 420 - Pages Notably, the refurbished medical devices have an advantage in terms of cost efficiency, so hospitals can manage their budgets much better, particularly in poorly funded healthcare systems or Enhanced Software Integration. The new-age refurbishment, with new components, makes…
PR Newswire
10/01/2025

Novo Holdings invests in $200M Series A for Windward Bio launch to advance…

Windward Bio's lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the potential to be dosed every six months. Windward Bio's lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal…
PR Newswire
10/01/2025

Samsung Bioepis and Teva Enter into a Strategic Partnership for…

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH) ,atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in the U .S .Partnership supports Teva's Pivot to Growth strategy and adds to its broad biosimilar portfolioINCHEON, Korea and TEL AVIV, Israel, Jan.10, 2025(GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical Industries Ltd...
Nasdaq GlobeNewswire
10/01/2025

Orexo announces positive topline data from clinical study of OX640 in subjects…

Topline data analysis demonstrates that OX640 treatments achieved mean epinephrine plasma levels associated with clinical efficacy more rapidly than the intramuscular injection, with dose-dependent exposure levels. Absorption under allergic rhinitis conditions was significantly faster than under normal conditions, supporting rapid onset of effect also in patients with significant airway symptoms. OX640 formulations typically produced more pronounced increases in blood pressure and heart rate…
PR Newswire
10/01/2025

Tiziana Announces Reduction of Side Effects Commonly Seen with Discontinuation…

GLP-1 drugs, widely used for treating metabolic disorders, often face issues with long term tolerability, leading to side effects such as sarcopenia and bone density loss. These complications frequently result in the discontinuation of GLP-1 therapies, reversing their beneficial effects on tissue homeostasis. Tiziana's nasal anti-CD3 therapy has been shown not only to enhance the positive effects of semaglutide, a GLP-1 agonist marketed by Novo Nordisk under the brand names Ozempic and...
Nasdaq GlobeNewswire
10/01/2025

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio…

/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today announced that it is amending the effective date for its plans to change the ratio of its American Depositary Shares (“ADSs”) to its ordinary shares, DKK 1 nominal value (the “ADS ratio”), from the current one (1) ADS representing ten (10) ordinary share to a new ADS ratio of one (1) ADS representing fifty (50) ordinary shares (the “ADS ratio change”).The ADS...
Nasdaq GlobeNewswire
10/01/2025

LGC Board appoints Joydeep Goswami as President & Chief Executive

David added: "On behalf of our Board, ELT and colleagues, we would also like to take this opportunity to thank Euan for his exceptional contribution to LGC. Prior to taking on Group-wide leadership responsibility in the summer of 2020, Euan led the expansion of LGC's Quality Assurance activities in the 2010s, substantially expanding our Standards business and establishing a leading presence in the clinical diagnostics and food supply chain assurance markets. As President and CEO, he has led…
PR Newswire
10/01/2025

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC- EOS-984 Phase 1 monotherapy and PD-1 combination data anticipated in 2H25- EOS-215, a potential best-in-class anti-TREM2 monoclonal antibody, IND submission anticipated in 1Q25- Cash balance and investment balance of $683.9 million as of September 30, 2024 expected to provide runway...
Nasdaq GlobeNewswire
10/01/2025

Diamyd Medical confirms key advances toward Accelerated Approval for Diamyd®…

Accelerated Approval Pathway: Confirmation that the ongoing DIAGNODE-3 Phase 3 trial aligns with requirements for an Accelerated Approval, leveraging interim efficacy data based on stimulated C-peptide as the primary endpoint from approximately 170 evaluable participants who will complete their 15-month assessments by early 2026. Accelerated Approval Pathway : Confirmation that the ongoing DIAGNODE-3 Phase 3 trial aligns with requirements for an Accelerated Approval, leveraging interim...
PR Newswire
10/01/2025

PCI Biotech: Employee share option scheme in connection with promotion of new…

In accordance with the authorisation granted by the Annual General Meeting 24 May 2024 and the remuneration policy adopted by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech Holding ASA (“PCI Biotech”) has awarded a total of 75,000 share options to a key employee. Each share option gives the right to subscribe for or acquire one share per option (after PCI Biotech's choice), at a strike price of NOK 1.35, equal to the volume weighted average share price (VWAP)...
Nasdaq GlobeNewswire
10/01/2025

NCCN Joins International Meeting to Improve Cancer Care in the Middle East and…

During the international meeting, experts from across the region will present new and updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): MENA Editions, and selected topics highlighting cancer advances, challenges, and opportunities in the MENA region. The NCCN Guidelines® provide evidence-based expert consensus-driven recommendations for cancer prevention, screening, treatment, and supportive care. NCCN Guidelines: MENA Editions tailor those best practices for unique…
PR Newswire
10/01/2025

Upgrade of revenue and operating profit guidance

ANNOUNCEMENT NO. 286 10 January 2025Upgrade of revenue and operating profit guidance ChemoMetec sustained its positive performance in the second quarter of 2024/25 with better-than-expected sales and order intake. The positive development is supported by the strengthening of the US dollar and continuous optimisation of operating costs.Based on this, the Company now expects revenue for the 2024/25 financial year in the DKK 470-490 million range, up from DKK 460-475 million in the...
Nasdaq GlobeNewswire
10/01/2025

David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics

David Schilansky, newly appointed Chief Financial Officer of Ariceum Therapeutics, commented: "I believe Ariceum is one of the most promising biotechs in Europe, gathering fantastic technology, the right positioning, a strong management team with a stellar group of shareholders. A breakthrough company in the radiopharma space, Ariceum's pipeline of novel candidates has the potential to transform the care of patients with aggressive cancers. These are crucial times for Ariceum and I look…
PR Newswire
10/01/2025

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on…

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (“THE CODE”). THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE.THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.For immediate release ...
Nasdaq GlobeNewswire
10/01/2025

Voting Rights and Shares Capital of the Company

In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Jan.09, 2025(GLOBE NEWSWIRE) --Paris, France, January 9, 2025Market: Euronext Paris / Nasdaq Euronext Compartment: BISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website:www.nanobiotix.comDateNumber of Shares OutstandingTotal number of voting rights...
Nasdaq GlobeNewswire
09/01/2025
Altri  Comunicati